These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 29688337)

  • 21. A small molecule p75NTR ligand normalizes signalling and reduces Huntington's disease phenotypes in R6/2 and BACHD mice.
    Simmons DA; Belichenko NP; Ford EC; Semaan S; Monbureau M; Aiyaswamy S; Holman CM; Condon C; Shamloo M; Massa SM; Longo FM
    Hum Mol Genet; 2016 Nov; 25(22):4920-4938. PubMed ID: 28171570
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Azadiradione Restores Protein Quality Control and Ameliorates the Disease Pathogenesis in a Mouse Model of Huntington's Disease.
    Singh BK; Vatsa N; Nelson VK; Kumar V; Kumar SS; Mandal SC; Pal M; Jana NR
    Mol Neurobiol; 2018 Aug; 55(8):6337-6346. PubMed ID: 29294248
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse.
    Chopra V; Fox JH; Lieberman G; Dorsey K; Matson W; Waldmeier P; Housman DE; Kazantsev A; Young AB; Hersch S
    Proc Natl Acad Sci U S A; 2007 Oct; 104(42):16685-9. PubMed ID: 17925440
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhanced mitochondrial biogenesis ameliorates disease phenotype in a full-length mouse model of Huntington's disease.
    Chandra A; Sharma A; Calingasan NY; White JM; Shurubor Y; Yang XW; Beal MF; Johri A
    Hum Mol Genet; 2016 Jun; 25(11):2269-2282. PubMed ID: 27008868
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Loss of striatal 90-kDa ribosomal S6 kinase (Rsk) is a key factor for motor, synaptic and transcription dysfunction in Huntington's disease.
    Anglada-Huguet M; Giralt A; Rué L; Alberch J; Xifró X
    Biochim Biophys Acta; 2016 Jul; 1862(7):1255-66. PubMed ID: 27063456
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preconditioning mesenchymal stem cells with the mood stabilizers lithium and valproic acid enhances therapeutic efficacy in a mouse model of Huntington's disease.
    Linares GR; Chiu CT; Scheuing L; Leng Y; Liao HM; Maric D; Chuang DM
    Exp Neurol; 2016 Jul; 281():81-92. PubMed ID: 27085395
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic Effects of Anthocyanins and Environmental Enrichment in R6/1 Huntington's Disease Mice.
    Kreilaus F; Spiro AS; Hannan AJ; Garner B; Jenner AM
    J Huntingtons Dis; 2016 Oct; 5(3):285-296. PubMed ID: 27567888
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of chronic stress on the onset and progression of Huntington's disease in transgenic mice.
    Mo C; Renoir T; Hannan AJ
    Neurobiol Dis; 2014 Nov; 71():81-94. PubMed ID: 25088714
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 mice.
    Apostol BL; Simmons DA; Zuccato C; Illes K; Pallos J; Casale M; Conforti P; Ramos C; Roarke M; Kathuria S; Cattaneo E; Marsh JL; Thompson LM
    Mol Cell Neurosci; 2008 Sep; 39(1):8-20. PubMed ID: 18602275
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting ENT1 and adenosine tone for the treatment of Huntington's disease.
    Kao YH; Lin MS; Chen CM; Wu YR; Chen HM; Lai HL; Chern Y; Lin CJ
    Hum Mol Genet; 2017 Feb; 26(3):467-478. PubMed ID: 28069792
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Altered selenium status in Huntington's disease: neuroprotection by selenite in the N171-82Q mouse model.
    Lu Z; Marks E; Chen J; Moline J; Barrows L; Raisbeck M; Volitakis I; Cherny RA; Chopra V; Bush AI; Hersch S; Fox JH
    Neurobiol Dis; 2014 Nov; 71():34-42. PubMed ID: 25014023
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ERK activation by the polyphenols fisetin and resveratrol provides neuroprotection in multiple models of Huntington's disease.
    Maher P; Dargusch R; Bodai L; Gerard PE; Purcell JM; Marsh JL
    Hum Mol Genet; 2011 Jan; 20(2):261-70. PubMed ID: 20952447
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model.
    Chou SY; Lee YC; Chen HM; Chiang MC; Lai HL; Chang HH; Wu YC; Sun CN; Chien CL; Lin YS; Wang SC; Tung YY; Chang C; Chern Y
    J Neurochem; 2005 Apr; 93(2):310-20. PubMed ID: 15816854
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metformin treatment reduces motor and neuropsychiatric phenotypes in the zQ175 mouse model of Huntington disease.
    Sanchis A; García-Gimeno MA; Cañada-Martínez AJ; Sequedo MD; Millán JM; Sanz P; Vázquez-Manrique RP
    Exp Mol Med; 2019 Jun; 51(6):1-16. PubMed ID: 31165723
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regulation of P-glycoprotein expression in brain capillaries in Huntington's disease and its impact on brain availability of antipsychotic agents risperidone and paliperidone.
    Kao YH; Chern Y; Yang HT; Chen HM; Lin CJ
    J Cereb Blood Flow Metab; 2016 Aug; 36(8):1412-23. PubMed ID: 26661162
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice.
    Stack EC; Smith KM; Ryu H; Cormier K; Chen M; Hagerty SW; Del Signore SJ; Cudkowicz ME; Friedlander RM; Ferrante RJ
    Biochim Biophys Acta; 2006 Mar; 1762(3):373-80. PubMed ID: 16364609
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Enhances Hippocampal Synaptic Plasticity and Improves Memory Performance in Huntington's Disease.
    Cabezas-Llobet N; Vidal-Sancho L; Masana M; Fournier A; Alberch J; Vaudry D; Xifró X
    Mol Neurobiol; 2018 Nov; 55(11):8263-8277. PubMed ID: 29526016
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Murine Models of Huntington's Disease for Evaluating Therapeutics.
    Kosior N; Leavitt BR
    Methods Mol Biol; 2018; 1780():179-207. PubMed ID: 29856020
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of Phosphodiesterases in Huntington's Disease.
    Fusco FR; Paldino E
    Adv Neurobiol; 2017; 17():285-304. PubMed ID: 28956337
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Progress in developing transgenic monkey model for Huntington's disease.
    Snyder BR; Chan AWS
    J Neural Transm (Vienna); 2018 Mar; 125(3):401-417. PubMed ID: 29127484
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.